Francisco Sousa Santos
Francisco Sousa Santos
Endocrinology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Francisco Sousa Santos in
Google Scholar
PubMed
Rita Joana Santos
Rita Joana Santos
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Search for other papers by Rita Joana Santos in
Google Scholar
PubMed
Valeriano Leite
Valeriano Leite
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Faculty of Medical Sciences of Lisbon, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
objective of inhibiting the MAPK pathway and angiogenesis [ 3 ]. Sorafenib, a TKI which inhibits VEGFR 1, 2, and 3, RET (including RET/PTC), RAF (including BRAFV600E), and platelet-derived growth factor receptor beta (PDGFRβ), has already been evaluated in
Laura Ximena Kattah Martinez
Laura Ximena Kattah Martinez
Pontificia Universidad Javeriana, Bogotá, Colombia
Search for other papers by Laura Ximena Kattah Martinez in
Google Scholar
PubMed
Search for other papers by Laura Ximena Kattah Martinez in
Google Scholar
PubMed
Lisseth Fernanda Marín Carrillo
Lisseth Fernanda Marín Carrillo
Pontificia Universidad Javeriana, Bogotá, Colombia
Search for other papers by Lisseth Fernanda Marín Carrillo in
Google Scholar
PubMed
Search for other papers by Lisseth Fernanda Marín Carrillo in
Google Scholar
PubMed
Leonardo Rojas Melo
Leonardo Rojas Melo
Pontificia Universidad Javeriana, Bogotá, Colombia
Search for other papers by Leonardo Rojas Melo in
Google Scholar
PubMed
Search for other papers by Leonardo Rojas Melo in
Google Scholar
PubMed
What Is Known About This Topic? Several side effects have been described with the use of tyrosine kinase inhibitors like sorafenib. Nonetheless, only 9 cases of pancreatitis related to sorafenib treatment have been described, all of them
Elisa Minaldi
Elisa Minaldi
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Elisa Minaldi in
Google Scholar
PubMed
Search for other papers by Elisa Minaldi in
Google Scholar
PubMed
Virginia Cappagli
Virginia Cappagli
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Search for other papers by Virginia Cappagli in
Google Scholar
PubMed
Loredana Lorusso
Loredana Lorusso
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Search for other papers by Loredana Lorusso in
Google Scholar
PubMed
Laura Valerio
Laura Valerio
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Search for other papers by Laura Valerio in
Google Scholar
PubMed
Carlotta Giani
Carlotta Giani
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Search for other papers by Carlotta Giani in
Google Scholar
PubMed
Matilde Viglione
Matilde Viglione
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Matilde Viglione in
Google Scholar
PubMed
Search for other papers by Matilde Viglione in
Google Scholar
PubMed
Laura Agate
Laura Agate
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Laura Agate in
Google Scholar
PubMed
Search for other papers by Laura Agate in
Google Scholar
PubMed
Eleonora Molinaro
Eleonora Molinaro
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed
Antonio Matrone
Antonio Matrone
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Search for other papers by Antonio Matrone in
Google Scholar
PubMed
Rossella Elisei
Rossella Elisei
Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Introduction Thanks to the results of DECISION and SELECT trials, sorafenib and lenvatinib are the only MKIs approved by both the U.S. Food and Drug Administration (FDA) and the European Medical Agency (EMA) for the first-line treatment of
Laura Fugazzola
Laura Fugazzola
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Rossella Elisei
Rossella Elisei
Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Dagmar Fuhrer
Dagmar Fuhrer
Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed
Barbara Jarzab
Barbara Jarzab
Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
Sophie Leboulleux
Sophie Leboulleux
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, Villejuif, France
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Kate Newbold
Kate Newbold
Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Jan Smit
Jan Smit
Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Jan Smit in
Google Scholar
PubMed
Search for other papers by Jan Smit in
Google Scholar
PubMed
.g. sorafenib and lenvatinib. The efficacy of both drugs has been demonstrated in phase III studies (DECISION study for sorafenib [ 13 ] and SELECT study for lenvatinib [ 14 ] and has been confirmed in “real-life” studies [ 15 - 19 ]. Although criteria for
Xian Qiu
Xian Qiu
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Search for other papers by Xian Qiu in
Google Scholar
PubMed
Search for other papers by Xian Qiu in
Google Scholar
PubMed
Lin Cheng
Lin Cheng
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Ri Sa
Ri Sa
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China
Search for other papers by Ri Sa in
Google Scholar
PubMed
Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China
Search for other papers by Ri Sa in
Google Scholar
PubMed
Hao Fu
Hao Fu
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
Search for other papers by Hao Fu in
Google Scholar
PubMed
Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
Search for other papers by Hao Fu in
Google Scholar
PubMed
Yuchen Jin
Yuchen Jin
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Libo Chen
Libo Chen
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Search for other papers by Libo Chen in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
, including chemotherapy and external beam radiation therapy, remains limited in these challenging settings. In recent years, tyrosine kinase inhibitors (TKIs) such as sorafenib and lenvatinib have highlighted new therapeutic options for the treatment of
Zoe A. Efstathiadou
Zoe A. Efstathiadou
Department of Endocrinology, “Hippokration” General Hospital of Thessaloniki, Thessaloniki, Greece
Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed
Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed
Charalambos Tsentidis
Charalambos Tsentidis
Department of Endocrinology, General Hospital of Nikaia “Agios Panteleimon”, Piraeus, Greece
Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed
Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed
Alexandra Bargiota
Alexandra Bargiota
Department of Endocrinology, University of Thessaly, Larisa, Greece
Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed
Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed
Vasiliki Daraki
Vasiliki Daraki
Department of Endocrinology, University Hospital of Crete, Heraklion, Greece
Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed
Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed
Kalliopi Kotsa
Kalliopi Kotsa
Department of Endocrinology, “Ahepa” Hospital, Aristotle University, Thessaloniki, Greece
Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed
Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed
Georgia Ntali
Georgia Ntali
Department of Endocrinology, Diabetes and Metabolism, “Evangelismos” Hospital Athens, Athens, Greece
Search for other papers by Georgia Ntali in
Google Scholar
PubMed
Search for other papers by Georgia Ntali in
Google Scholar
PubMed
Labrini Papanastasiou
Labrini Papanastasiou
Department of Endocrinology and Diabetes Center, Athens General Hospital “G. Gennimatas”, Athens, Greece
Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed
Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed
Stelios Tigas
Stelios Tigas
Department of Endocrinology, University of Ioannina, Ioannina, Greece
Search for other papers by Stelios Tigas in
Google Scholar
PubMed
Search for other papers by Stelios Tigas in
Google Scholar
PubMed
Konstantinos Toulis
Konstantinos Toulis
Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece
Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed
Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed
Kalliopi Pazaitou-Panayiotou
Kalliopi Pazaitou-Panayiotou
Division of Endocrinology, Endocrine Oncology, Interbalkan Medical Center, Thessaloniki, Greece
Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed
Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed
Maria Alevizaki
Maria Alevizaki
Endocrine Unit, Department of Medical Therapeutics, School of Medicine, Kapodistrian University of Athens, Athens, Greece
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
Search for other papers by Maria Alevizaki in
Google Scholar
PubMed
cabozantinib OR crizotinib OR dasatinib OR erlotinib OR imatinib OR ibrutinib OR lapatinib OR midostaurin OR neratinib OR nilotinib OR pacritinib OR pazopanib OR ponatinib OR regorafenib OR sorafenib OR sunitinib OR vandetanib OR ziv-aflibercept OR gefitinib OR
Daniela Dias
Daniela Dias
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Daniela Dias in
Google Scholar
PubMed
Search for other papers by Daniela Dias in
Google Scholar
PubMed
Inês Damásio
Inês Damásio
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Search for other papers by Inês Damásio in
Google Scholar
PubMed
Pedro Marques
Pedro Marques
Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisbon, Portugal
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Search for other papers by Pedro Marques in
Google Scholar
PubMed
Helder Simões
Helder Simões
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Helder Simões in
Google Scholar
PubMed
Search for other papers by Helder Simões in
Google Scholar
PubMed
Ricardo Rodrigues
Ricardo Rodrigues
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
Branca Maria Cavaco
Branca Maria Cavaco
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed
Valeriano Leite
Valeriano Leite
Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
MKIs sorafenib and lenvatinib for the treatment of metastatic progressive differentiated thyroid cancer (DTC) of follicular origin. These drugs now play a major role as first-line targeted therapy for such tumors. Progression-free survival was 10
Kirsten E. Stewart
Kirsten E. Stewart
Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom
Search for other papers by Kirsten E. Stewart in
Google Scholar
PubMed
Search for other papers by Kirsten E. Stewart in
Google Scholar
PubMed
Mark W.J. Strachan
Mark W.J. Strachan
Metabolic Unit, Western General Hospital, Edinburgh, United Kingdom
Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed
Search for other papers by Mark W.J. Strachan in
Google Scholar
PubMed
Devraj Srinivasan
Devraj Srinivasan
Department of Oncology, Western General Hospital, Edinburgh, United Kingdom
Search for other papers by Devraj Srinivasan in
Google Scholar
PubMed
Search for other papers by Devraj Srinivasan in
Google Scholar
PubMed
Morna MacNeill
Morna MacNeill
Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Search for other papers by Morna MacNeill in
Google Scholar
PubMed
Search for other papers by Morna MacNeill in
Google Scholar
PubMed
Lucy Wall
Lucy Wall
Department of Oncology, Western General Hospital, Edinburgh, United Kingdom
Search for other papers by Lucy Wall in
Google Scholar
PubMed
Search for other papers by Lucy Wall in
Google Scholar
PubMed
Iain J. Nixon
Iain J. Nixon
Department of Head and Neck Surgery, St John’s Hospital at Howden, Livingston, United Kingdom
Search for other papers by Iain J. Nixon in
Google Scholar
PubMed
Search for other papers by Iain J. Nixon in
Google Scholar
PubMed
deemed unsuitable for surgery, limited alternative options were available. Sorafenib and lenvatinib both showed a prolonged progression-free survival advantage in patients with radioactive iodine-refractory differentiated thyroid cancer (DTC
Marine Sitbon
Marine Sitbon
Pharmacy Department, Hospital Saint-Louis APHP, Paris, France
Search for other papers by Marine Sitbon in
Google Scholar
PubMed
Search for other papers by Marine Sitbon in
Google Scholar
PubMed
Porhuoy Chou
Porhuoy Chou
Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France
Search for other papers by Porhuoy Chou in
Google Scholar
PubMed
Search for other papers by Porhuoy Chou in
Google Scholar
PubMed
Seydou Bengaly
Seydou Bengaly
Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France
Search for other papers by Seydou Bengaly in
Google Scholar
PubMed
Search for other papers by Seydou Bengaly in
Google Scholar
PubMed
Brigitte Poirot
Brigitte Poirot
Department of Molecular Oncology, Saint-Louis Hospital (AP-HP), Université Paris Cité INSERM U 944, CNRS UMR 7212, Paris, France
Search for other papers by Brigitte Poirot in
Google Scholar
PubMed
Search for other papers by Brigitte Poirot in
Google Scholar
PubMed
Marie Laloi-Michelin
Marie Laloi-Michelin
Department of Internal Medicine, Hospital Lariboisière APHP, Paris, France
Search for other papers by Marie Laloi-Michelin in
Google Scholar
PubMed
Search for other papers by Marie Laloi-Michelin in
Google Scholar
PubMed
Laure Deville
Laure Deville
Pharmacy Department, Hospital Saint-Louis APHP, Paris, France
Search for other papers by Laure Deville in
Google Scholar
PubMed
Search for other papers by Laure Deville in
Google Scholar
PubMed
Atanas Pachev
Atanas Pachev
Radiology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France
Search for other papers by Atanas Pachev in
Google Scholar
PubMed
Search for other papers by Atanas Pachev in
Google Scholar
PubMed
Ahouefa Kowo-Bille
Ahouefa Kowo-Bille
Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France
Search for other papers by Ahouefa Kowo-Bille in
Google Scholar
PubMed
Search for other papers by Ahouefa Kowo-Bille in
Google Scholar
PubMed
Clement Dumont
Clement Dumont
Medical Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France
Search for other papers by Clement Dumont in
Google Scholar
PubMed
Search for other papers by Clement Dumont in
Google Scholar
PubMed
Cécile N Chougnet
Cécile N Chougnet
Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France
Search for other papers by Cécile N Chougnet in
Google Scholar
PubMed
Search for other papers by Cécile N Chougnet in
Google Scholar
PubMed
patient refused vandetanib treatment. Similarly, another team showed a rapid response with sorafenib, but sorafenib was not approved for MTC ( 10 ). Here, we report successful treatment of Cushing’s syndrome with RET-targeted therapy in a patient with
Jihwan Yoo
Jihwan Yoo
Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Seoul, Republic of Korea
College of Medicine, Yonsei University, Seoul, Republic of Korea
Search for other papers by Jihwan Yoo in
Google Scholar
PubMed
College of Medicine, Yonsei University, Seoul, Republic of Korea
Search for other papers by Jihwan Yoo in
Google Scholar
PubMed
Hee Jun Kim
Hee Jun Kim
Department of Surgery, CHA Ilsan Medical Center, Cha University School of Medicine, Goyang-si, Republic of Korea
Search for other papers by Hee Jun Kim in
Google Scholar
PubMed
Search for other papers by Hee Jun Kim in
Google Scholar
PubMed
Seok Mo Kim
Seok Mo Kim
Department of Surgery, Thyroid Cancer Center, Gangnam Severance Hospital, Institute of Refractory Thyroid Cancer, Yonsei University College of Medicine, Seoul, Republic of Korea
Search for other papers by Seok Mo Kim in
Google Scholar
PubMed
Search for other papers by Seok Mo Kim in
Google Scholar
PubMed
Hun Ho Park
Hun Ho Park
Department of Neurosurgery, Brain Tumor Center, Gangnam Severance Hospital, Seoul, Republic of Korea
Search for other papers by Hun Ho Park in
Google Scholar
PubMed
Search for other papers by Hun Ho Park in
Google Scholar
PubMed
number of brain metastases). Progressive thyroid cancer was preferentially treated with RAI therapy; TKIs, including sorafenib or lenvatinib, were administered when the cumulative RAI dose exceeded 600 mCi. Following the confirmation of brain metastasis
